Abbott Laboratories (NYSE:ABT) Issues FY 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 5.450-5.60 for the period, compared to the consensus EPS estimate of 5.480. The company issued revenue guidance of -. Abbott Laboratories also updated its Q3 2026 guidance to 1.380-1.46 EPS.

Analyst Ratings Changes

A number of research firms recently issued reports on ABT. Benchmark decreased their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Mizuho reduced their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Evercore decreased their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. UBS Group lowered their price target on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Finally, Leerink Partners dropped their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $117.61.

Abbott Laboratories Price Performance

NYSE ABT opened at $89.27 on Thursday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company has a market cap of $155.49 billion, a PE ratio of 25.01, a price-to-earnings-growth ratio of 1.53 and a beta of 0.61. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The firm’s 50-day simple moving average is $89.33 and its two-hundred day simple moving average is $102.36.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. Abbott Laboratories’s payout ratio is presently 70.59%.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Analysts expect Abbott’s upcoming Q2 results to show healthy revenue and earnings growth, supported by strong performance in Diagnostics, Devices and Emerging Pharmaceutical/EPD segments. Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition
• Positive Sentiment: Coverage around Abbott’s cancer diagnostics strategy highlights longer-term growth potential, with management continuing to invest in improving tests and expanding the business after the Exact Sciences acquisition. Abbott’s cancer diagnostics vision: ‘There’s always a hunger to make these tests better’
• Positive Sentiment: Analysts are still recommending investors retain Abbott shares for now, citing emerging-market pharmaceutical growth and continued innovation in nutrition as potential supports for the stock. Reasons to Retain Abbott Stock in Your Portfolio for Now
• Neutral Sentiment: Market commentary says Abbott is one of the names investors are watching as earnings season begins, but the article is mainly a watchlist note rather than fresh company-specific news. UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday
• Neutral Sentiment: Another brief market note also flags Abbott ahead of earnings, reinforcing that the stock is being traded around the upcoming results. UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday
• Negative Sentiment: Risks remain from macro pressure and foreign exchange swings, which could weigh on results even if core business trends stay healthy. Reasons to Retain Abbott Stock in Your Portfolio for Now
• Negative Sentiment: Nutrition remains a drag in the near term, and some coverage notes that this segment could limit upside if other divisions do not fully offset it. Abbott’s Q2 Earnings on Deck: How Should You Play the Stock Now?

Hedge Funds Weigh In On Abbott Laboratories

A number of large investors have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in Abbott Laboratories during the 4th quarter worth approximately $583,000. Compound Planning Inc. boosted its holdings in Abbott Laboratories by 53.5% in the 4th quarter. Compound Planning Inc. now owns 37,315 shares of the healthcare product maker’s stock valued at $4,675,000 after purchasing an additional 13,010 shares during the period. Claris Financial LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at $307,000. Strive Financial Group LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at $539,000. Finally, Blue Sparrow LLC DE bought a new position in shares of Abbott Laboratories in the fourth quarter worth $1,842,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.